Atypical antipsychotic use for adult outpatients in New Zealand's Auckland and Northland regions

New Zealand Medical Journal

Volumn 119, Issue 1237, 2006, Pages

  Wheeler, Amanda ^a  

^a WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PENFLURIDOL; PIPOTIAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANXIETY DISORDER; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG PREFERENCE; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD DISORDER; NEW ZEALAND; OUTPATIENT CARE; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHOSIS; RETROSPECTIVE STUDY; REVIEW; SCHIZOPHRENIA; AMBULATORY CARE; ARTICLE; DRUG COMBINATION; MIDDLE AGED; STATISTICS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; NEW ZEALAND; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES; RISPERIDONE;

EID: 33746340928     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry. 2003;60:553-64.
2. Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews. 2000:CD000059.
3. Azorin JM, Spiegel R, Remington G, et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. American Journal of Psychiatry. 2001;158:1305-13.
4. Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs. 2004;18:877-93.
5. Anonymous. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry. 2005;39:1-30.
6. Ministry of Health. Moving Forward: The National Mental Health Plan for More and Better Services. Wellington: Ministry of Health, 1997.
7. Ministry of Health. Looking Forward: Strategic Directions for the Mental Health Services. Wellington: Ministry of Health; 1994.
8. Pharmaceutical Management Agency. Annual Review 2003. Wellington: Pharmaceutical Management Agency (PHARMAC); 2003.
9. Walker RA. 2001 Demographic Profile for Counties Manukau District Health Board: An Analysis of 2001 Census. Auckland: Regional Decision Support Team, Northern DHB Support Agency (NDSA); 2002.
10. Walker RA. 2001 Demographic Profile for Waitemata District Health Board: An Analysis of 2001 Census. Auckland: Regional Decision Support Team, Northern DHB Support Agency (NDSA); 2002.
11. Walker RA. 2001 Demographic Profile for Auckland District Health Board: An Analysis of 2001 Census. Auckland: Regional Decision Support Team, Northern DHB Support Agency (NDSA); 2002.
12. Walker RA. 2001 Demographic Profile for Northland District Health Board: An Analysis of 2001 Census. Auckland: Regional Decision Support Team, Northern DHB Support Agency (NDSA); 2002.
13. Frangou S, Lewis M. Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service. European Psychiatry. 2000;15:220-6.
14. Rosenheck R, Leslie D, Sernyak M. From clinical trials to real-world practice: use of atypical antipsychotic medication nationally in the Department of Veterans Affairs. Medical Care. 2001;39:302-8.
15. Mond J, Morice R, Owen C, Korten A. Use of antipsychotic medications in Australian States and Territories between July 1995 and December 2001. Australian and New Zealand Journal of Psychiatry. 2003;37:55-61.
16. Bagnall AM, Jones L, Ginnelly L, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technology Assessment (Winchester, England) 2003;7:1-193.
17. Meltzer HY. Treatment-resistant schizophrenia - the role of clozapine. Current Medical Research & Opinion. 1997;14:1-20.
18. Keks NA, Altson K, Hope J, et al. Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry. 1999;33:896-901
19. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. British Journal of Psychiatry. 1997;171:569-73.
20. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. American Journal of Psychiatry. 2005;162:130-6.
21. Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. Journal of Clinical Psychiatry. 2004;65:500-8.